非小细胞肺癌顺铂化疗耐药相关微RNA的筛选及鉴定

 目的　探讨肿瘤细胞微RNA（miRNA）对化疗药物敏感性的作用。方法　通过miRNA芯片技术检测顺铂（DDP）耐药细胞株A549／DDP与非耐药细胞株A549的miRNA表达的差异,利用荧光定量聚合酶链反应（PCR）技术验证相应miRNA的表达情况,通过在细胞株中抑制或过表达目标miRNA,研究其对细胞化疗药物敏感性的影响。结果　A549／DDP细胞对DDP的耐药为A549细胞的18倍。A549／DDP细胞与A549细胞存在51个表达水平差异在4倍以上的miRNA,其中24个表达上调,27个表达下调。PCR进一步证实miR-376c、miR-31、miR-29a、miR-221在A549／DDP细胞中显著上调,miR-196a、miR-20a、miR-20b、miR-17、miR-451在A549／DDP细胞中显著下调。在提高A549／DDP细胞中miR-17的表达后,细胞对DDP的敏感度增加了11.7 %,提高miR-451的表达或者抑制miR-29a的表达后,对DDP的敏感度分别下降了15.5 %、12.9 %,抑制miR-376c、miR-31、miR-221或过表达miR-196a、miR-20a、miR-20b均不影响A549／DDP细胞对DDP的敏感度。结论　非小细胞肺癌DDP耐药细胞与非耐药细胞的miRNA表达谱有差异,miRNA参与肺癌化疗耐药,miR-17具有逆转非小细胞肺癌DDP耐药的潜力。     

靶向PTEN的肿瘤相关微小RNA

微小RNA (miRNA)是通过基因转录后沉默来调控基因表达的内源性非编码小RNA.其中miR-21、miR-17-92、miR-214、miR-26a、miR-221、miR-222等可以通过与PTEN mRNA 3'-UTR互补结合来抑制PTEN磷酸水解酶表达,而PTEN在细胞的增殖、凋亡、转移与侵袭中发挥重要作用...     

microRNA-128： 肿瘤治疗新靶点

微小RNA（miRNA）是体内一类长度为21～25个核苷酸的内源性非编码单链RNA,其主要通过完全或不完全互补结合至靶基因的3’非编码区而调控靶基因的表达。miRNA有多种类型,其中miR-128在多种疾病和正常组织中均不同程度的表达,具有广泛的调节作用。研究发现miR-128参与了神经胶质瘤、白血病、胃癌、肺癌及乳腺癌的发生过程,对细胞的分化、增殖、迁移和凋亡有重要作用。本文就miR-128在肿瘤中的研究进行详细阐述,以期为肿瘤的治疗提供新的靶点。     

微RNA-106b～25基因簇在肿瘤中的研究进展

微RNA(miRNA)-106b～25基因簇由miR-106b、miR-93及miR-25组成,与miR-17～92原癌基因簇有着极高的同源性.已有的研究表明,该簇miRNA成员在多种肿瘤中高表达.这些miR通过抑制细胞周期抑制因子p21、p57及凋亡抑制因子Bim来促进肿瘤细胞增殖,抑制细胞凋亡.在转化生长因子β(T...     

成骨肉瘤细胞SOSP-9607中miRNA的克隆与验证

背景与目的:microRNA(miRNA)是一类非编码蛋白,并参与转录后调节的单链小分子RNA(约20～25个碱基),对基因表达具有重要调控作用,与肿瘤的发生存在着密切的关系.本研究拟克隆成骨肉瘤细胞系SOSP-9607中miRNA,并对部分功能性基因进行验证.方法:以SOSP-9607细胞作为实验对象,分离提取细胞内小片段RNA(≤200 nt),多聚腺苷酸化和5'连接子连接后,通过RT-PCR进行反转录和扩增,克隆到pCR 4-TOPO载体上得到大约109 bp DNA片段,测序后经过生物信息学分析确定miRNA的表达情况.根据当前miRNA的研究现状,在克隆到的miRNA中选取部分功能性miRNA和新发现miRNA,合成相应探针后与从SOSP-9607细胞、HeLa细胞和成骨肉瘤组织中分离出的小片段RNA进行Northern印迹验证.结果:克隆测序后得到182个克隆体,经生物信息学分析发现有47个miRNA(25种),其中含有23种已知的miRNA和2种Nature杂志上预测的miRNA(miR-165和miR-166).选取的三条实体瘤相关的miRNA(miR-21、miR-20a、miR-17-5p)以及两条预测的miRNA进行Northern印迹验证,miR-21、miR-20a、miR-17-5p在SOSP-9607细胞和成骨肉瘤组织中均表达,预测的miR-165和miR-166在SOSP-9607细胞和成骨肉瘤组织中亦均表达,但miR-166在HeLa细胞中没有表达.结论:克隆了SOSP-9607细胞中的miRNA,并验证了部分功能性miRNA的表达,提示miRNA与肿瘤发生可能有密切的关系.     

微小RNA在肿瘤基因中的研究进展

微小RNA(miRNA)是近年来发现的一类长度为19～25碱基的非编码小分子单链RNA,普遍存在于生物界,在不同物种间具有高度的保守性,其表达具有细胞特异性或组织特异性.通过与miRNA特异性的碱基完全或不完全的互补配对,降解其靶基因miRNA或抑制其翻译,从而参与肿瘤细胞的增殖、分化和细胞凋亡过程.miRNA可通过调控其靶基因,影响肿瘤的发生和发展,发挥着类似于癌基因或抑癌基因的功能.目前研究表明,miRNA与肿瘤的发生相关.阐明miRNA与肿瘤基因的关系,对其作为癌症潜在的治疗靶点具有重要意义.     

microRNA及其在淋巴瘤中的表达

 micro RNA（miRNA）是一类长度大约为22 nt的非编码小片段RNA，其进化保守，通过与mRNA的3'UTR相互作用进而调控mRNA的翻译，广泛作用于发育、炎症、凋亡和肿瘤等各个生物学过程。在T淋巴瘤中发现miR-106a和miR-17-92过度表达；在弥漫性大B细胞淋巴瘤和滤泡细胞淋巴瘤中的miR-155，miR-221和miR-21表达上调，并与肿瘤的亚型有关。miR-17 簇过度表达可使凋亡水平下降，表明这些miRNA的主要作用是抑制细胞的死亡。miRNA既可促进肿瘤的发生，又能抑制肿瘤，但其确切机制尚不明。随着研究的深入，miRNA的遗传表型调节功能将会越来越清楚。     

miR-367-3p在非小细胞肺癌组织中的表达及对细胞功能的影响

目的:研究miR-367-3p在非小细胞肺癌（non-small cell lung cancer，NSCLC）中促进肿瘤生长的作用机制。方法:收集非小细胞肺癌患者的临床标本，检测miR-367-3p在非小细胞肺癌组织中的表达。利用qRT-PCR、MTT和流式细胞术分别评估miR-367-3p的表达改变对肿瘤细胞增殖和周期的影响。Western blot检测miR-367-3p表达改变对FBXW7的影响。双荧光素酶实验验证miR-367-3p与FBXW7之间的直接关系。结果:miR-367-3p在非小细胞肺癌组织中的表达明显高于对应癌旁组织。miR-367-3p作为促癌的miRNA，在非小细胞肺癌细胞中促进肿瘤细胞增殖和细胞周期进程。miR-367-3p对NSCLC细胞生物学功能的影响部分依赖靶向抑制FBXW7。结论:miR-367-3p通过靶向抑制FBXW7的表达促进NSCLC细胞增殖和周期。     

miRNA与非小细胞肺癌的研究进展

微小RNA（miRNA）是人类基因组中广泛存在的一类非编码单链小分子RNA,在转录后水平以完全或非完全互补的方式与其靶mRNA相结合,调节相应mRNA表达,影响生物学性状。研究发现miRNA的重要进程包括基因表达调控、细胞增殖分化等与肿瘤密切相关。目前miRNA在非小细胞肺癌的研究尚处于起步阶段,主要包括miRNA在非小细胞肺癌中的表达检测;miRNA与非小细胞肺癌的发生、预后的相关性及其机制的研究;以及miRNA在NSCLC的诊断、治疗及预后判断等方面的应用。     

miRNA在肿瘤研究中的应用

miRNA是一种小RNA分子,通过抑制蛋白质翻译来控制基因的表达.miRNA的表达及其甲基化与肿瘤的形成有密切关系.人类RNA干扰途径起源于细胞核,通过miRNA介导的RNAi基因治疗能够抑制癌基因和与肿瘤进展相关的基因.应用miRNA介导的RNA干扰技术治疗癌症,有可能克服目前癌症治疗中的诸多难题.     

miR-148a 靶向HMGB3抑制非小细胞肺癌细胞迁移、侵袭和增强顺铂抗肿瘤效应的机制研究

目的:探讨miR-148a靶向HMGB3抑制非小细胞肺癌细胞迁移和侵袭的作用机制。方法:采用RT-qPCR和Western blot检测非小细胞肺癌组织和癌旁组织标本中miR-148a和HMGB3相对表达水平;以A549、H1299细胞为研究对象,Transwell和MTT法分别检测过表达miR-148a、敲低HMGB3和DDP干预对细胞迁移、侵袭及细胞活力的影响;TargetScan在线预测、双荧光素酶报告基因实验和Western blot验证miR-148a与HMGB3的靶向关系;miR-148a过表达或敲减HMGB3并联合DDP,Transwell和MTT法检测细胞迁移、侵袭和细胞活力。结果:非小细胞癌组织中miRNA-148a表达明显下调（P<0.05）,HMGB3在mRNA和蛋白水平表达均明显上调（P<0.05）,miR-148a与HMGB3表达呈负相关（r=-0.856 8,P<0.000 1）;过表达miR-148a或敲低HMGB3能明显抑制细胞迁移和侵袭（P<0.05）,过表达miR-148a或敲低HMGB3联合DDP干预,细胞活力明显下降（P<0.05）;TargetScan在线预测、双荧光素酶报告基因实验和Western blot检测表明miR-148a能调控HMGB3表达。结论:miR-148a在非小细胞肺癌组织中表达下调,HMGB3是miR-148a的靶基因,过表达miR-148a能抑制HMGB3表达从而抑制非小细胞肺癌细胞A549、H1299迁移和侵袭并增强顺铂抗肿瘤效应。     

MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.     

miR-940在非小细胞肺癌中的表达及对肺腺癌A549细胞生物学功能的影响北大核心

目的:探讨miR-940在非小细胞肺癌中的表达及对肺腺癌A549细胞增殖、迁移、侵袭的影响。方法:选取标本库中2015年10月至2016年12月在我院胸外二科行手术治疗的非小细胞肺癌患者85例,检测癌组织和癌旁组织中miR-940的表达水平。将miR-940 mimics和miR-940 inhibitors转染至A549细胞中,检测转染后各组A549细胞中miR-940的表达水平。根据细胞增殖实验、划痕实验和Transwell实验检测各组细胞的增殖、迁移及侵袭能力变化。双荧光素酶实验证实miR-940的靶基因。结果:miR-940在癌组织中的表达量显著低于癌旁组织中的表达量,差异有统计学意义(P=0.004)。细胞增殖实验结果显示,miR-940 mimics组的细胞增殖率显著低于miR-940 inhibitors组(P<0.05);细胞划痕实验结果显示,miR-940 mimics组的划痕愈合率明显低于miR-940 inhibitors组(P<0.05);Transwell细胞侵袭实验结果显示,miR-940 mimics组的侵袭细胞数显著低于miR-940 inhibitors组的侵袭细胞数,差异有统计学意义(P<0.01)。Cbl-b是miR-940的直接靶基因。结论:miR-940在非小细胞肺癌中呈低表达,miR-940可能通过靶向抑制Cbl-b基因,进而抑制A549细胞的增殖、迁移和侵袭能力。     

miR-363-3p和miR-5100在非小细胞肺癌中的表达及其临床意义

目的:探讨小分子RNA(microRNA)miR-363-3p 和miR-5100在非小细胞肺癌中的表达及其临床意义.方法:利用荧光定量PCR的方法,检测肿瘤组织、癌旁组织及远离肿瘤的正常组织中致癌基因Myc的mRNA 和miR-363-3p、miR-5100的表达,然后分析miR-363-3p 和miR-5100与临床病理特征之间的相关性.结果:Myc在肿瘤组织中表达明显升高;miR-363-3p在肺癌组织中的表达明显低于正常组织(P<0.001),而在癌旁组织中的表达却远远高于正常组织(P<0.05);miR-5100在肺癌组织中的表达显著地高于正常组织(P<0.001),并且癌旁组织中的表达也高于正常组织(P<0.05).临床相关性分析显示,miR-363-3p的表达与淋巴结转移呈正相关(P<0.001),miR-5100的表达与临床分期也呈正相关性(P<0.05).结论:miR-363-3p 和miR-5100可能参与了非小细胞肺癌早期的发生和转移,并可能作为早期诊断和预后的分子标志物.     

The novel miR-9501 inhibits cell proliferation,migration and activates apoptosis in non-small cell lung cancer

Accumulating evidences suggest that lots of microRNAs (miRNAs) play crucial roles in (patho-)physiological processes of lung cancer, including metastasis, drug-resistance or tumorigenesis. They mediate the progression of cell growth, migration and invasion by regulating the expression of special genes. MiRNA expression patterns could also serve as diagnostic/prognostic biomarkers. Cancer therapies mediated by miRNAs remain tremendous potential and challenges. Our previous small RNA-seq assay found that the novel miR-9501 was down-regulated in lung cancer tissues compared with adjacent non-cancer tissues. In this study, our results verified that miR-9501 was significantly down-regulated in lung cancer tissues and its expression levels were remarkably suppressed in non-small cell lung cancer cell lines. Then, we characterized and investigated the novel miR-9501 in A549 cells. Transient transfection of miR-9501 into cultured A549 cells led to remarkable decrease in cell proliferation, migration and increase apoptosis. These data demonstrated that miR-9501 might be a tumor suppressor for lung cancer therapy.     

miR-590在恶性肿瘤中的研究进展

微小RNA（microRNA,miRNA,miR）是一类小的单链非编码RNA,长度为18~25个核苷酸,通过与mRNA的3' 非翻译区（3' untranslated region,3' UTR）中不完全匹配的序列来沉默基因表达,具有高度保守的序列。越来越多的研究已经在各种类型的恶性肿瘤中观察到miRNA,并且发现miRNA参与调节癌细胞行为,包括细胞增殖、凋亡、迁移和侵袭。miR-590的表达和功能在不同类型的肿瘤中并不相同,其表达的失调与恶性肿瘤的发生发展、治疗及预后密切相关。本文就miR-590在各种恶性肿瘤中的最新研究进展作一综述。     

MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis

Lung cancer is the leading cause of cancer deaths in the world. Brain metastasis (BM) can affect about 25% of non-small cell lung cancer (NSCLC) patients during their lifetime. Efforts to characterize patients that will develop BM have been disappointing. MicroRNAs (miRNAs) play a role in regulating a variety of targets and, consequently, multiple pathways, which make them a powerful tool for early detection of disease, risk assessment and prognosis. In this study, using RT-PCR and further northern blot validation, we confirmed that miR-378 was significantly differentially expressed in the matched NSCLC from 8 patients with BM and 21 without BM. Our study showed evidences that miR-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. MiR-378 may be a potential biomarker for characterizing non-small cell lung cancer brain metastasis and assisting clinicians in stratifying the high-risk patients on a clinical trial for either prophylactic cranial irradiation or a new intervention that may mitigate BM development, ultimately leading to a new standard of care for NSCLC patients.     

Linc00052基因在非小细胞肺癌中的表达及临床意义

目的:探究非小细胞肺癌(NSCLC)组织及其细胞系内基因长链非编码RNA00052(long intergenic non-coding RNA 00052,Linc00052)的表达水平,以及Linc00052在肺癌中的临床意义、作用机制及与患者预后的相关性。方法:利用逆转录-聚合酶链反应(qRT-PCR)检测正常肺细胞系与肺癌细胞系之间Linc00052表达水平的差异,肺癌组织与癌旁组织之间Linc00052表达水平的差异,并分析Linc00052与肺癌临床病理特征的相关性,Kaplan-Meier生存曲线分析Linc00052与肺癌预后之间的相关性。在A549细胞系中过表达Linc00052,采用MTT实验检测过表达Linc00052前后细胞增殖变化,并采用qRT-PCR检测miR-330-3p表达变化。结果:肺癌细胞系较正常肺细胞系中Linc00052明显低表达,同时肺癌组织比癌旁组织中Linc00052明显低表达(P＜0.01);Linc00052的表达与肿瘤的分化程度（P=0.02）、淋巴结转移（P=0.002）、远处转移（P=0.005）和临床分期（P=0.001）有关。肺癌的Linc00052表达水平减低与肺癌患者的预后不良有关（P＜0.05）。过表达Linc00052后可显著抑制细胞增殖（P＜0.05）,qRT-PCR结果证实,过表达Linc00052可显著下调miR-330-3p mRNA的表达水平（P＜0.05）。结论:Linc00052在肺癌组织中表达下调,并与肺癌的发生发展及预后密切相关,Linc00052有可能通过负调控miR-330-3p在肺癌中发挥抑癌作用。     

MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells

Metastasis-associated gene 1 (MTA1) is involved in the carcinogenesis and metastasis of many human carcinomas. However, its exact role in non-small cell lung cancer (NSCLC) is still unclear. Using immunohistochemistry analysis, we recently identified MTA1 to be associated with the progression of NSCLC. Here, we carried out further analysis on the effect of MTA1 knockdown in an NSCLC cell line on cell functions and the global microRNA (miRNA) expression profile. We succeeded in establishing the MTA1 knockdown NSCLC cell line using RNA interference (RNAi), and found that the silencing of MTA1 resulted in the effective inhibition of the invasive ability of NSCLC cells, but not of the cell growth in vitro. We performed an miRNA microarray analysis and demonstrated for the first time that MTA1 knockdown significantly changed the expression of some miRNAs in NSCLC cells. Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression. The interaction between MTA1 and the miRNAs which contributes to lung cancer is worthy of further investigation.     

MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN

MicroRNAs (miRNAs) are involved in human cancer including non-small cell lung cancer (NSCLC). In this study, we compared miRNA expression microarray of SPC-A-1sci (high metastatic) and SPC-A-1 (weakly metastatic) cells. We found that miRNA-10a was up-regulated in NSCLC compared with corresponding normal tissues. High expression of miR-10a was associated with tumor node metastasis and lymph node metastasis. Furthermore, overexpression of miR-10a promoted NSCLC cell proliferation, migration and invasion in vitro. We found that PTEN was a direct target of miR-10a in NSCLC. Also miR-10a activated the PTEN/AKT/ERK pathway. We suggest that miR-10a contributes to NSCLC by targeting PTEN.